Bacitracin - Revision history

ClaireLewis at 21:29, 19 September 2019

2019-09-19T21:29:03Z

← Older revision		Revision as of 21:29, 19 September 2019
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type: Topical antibiotic		*Type: Topical [[antibiotic]]
	*Dosage Forms: ointment		*Dosage Forms: ointment
	*Dosage strengths: 500 unit/g		*Dosage strengths: 500 unit/g
Line 49:		Line 49:

	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]] [[Category:ID]]

Fletc151: /* References */

2019-06-10T13:11:16Z

References

← Older revision		Revision as of 13:11, 10 June 2019
Line 40:		Line 40:

	==References==		==References==
			*BACiiM (bacitracin) [prescribing information], Horseheads, NY: X-Gen Pharmaceuticals Inc; June 2008.
			*Bacitracin (prescribing information). New York, NY: Pharmacia & Upjohn; September 2015.
			*Chia JK, Nakata MM, Park SS, et al, “Use of Bacitracin Therapy for Infection Due to Vancomycin-Resistant Enterococcus faecium,” Clin Infect Dis, 1995, 21(6):1520. [PubMed 8749657]
			*Cohen SH, Gerding DN, Johnson S, et al, “Clinical Practice Guidelines for Clostridium difficile Infection in Adults: 2010 Update by the Society for healthcare Epidemiology of American (SHEA) and the Infectious Diseases Society of America (IDSA), Infect Control Hosp Epidemiol, 2010, 31(5):431-55. [PubMed 20307191]
			*Damm S. Intraoperative anaphylaxis associated with bacitracin irrigation. Am J Health-Syst Pharm. 2011;68(4):323-327. [PubMed 21289327]
			*Dudley MN, McLaughlin JC, Carrington G, et al, “Oral Bacitracin vs Vancomycin Therapy for Clostridium difficile-Induced Diarrhea. A Randomized Double-Blind Trial,” Arch Intern Med, 1986, 146(6):1101-4.
			*Elsner P, Pevny I, Burg G. Anaphylaxis induced by topically applied bacitracin. Am J Contact Dermat.1990;1:162-164.

	<references/>		<references/>
	[[Category:Pharmacology]]		[[Category:Pharmacology]]

Humanguy: /* Pharmacology */ added excretion

2017-10-11T22:34:34Z

Pharmacology: added excretion

← Older revision		Revision as of 22:34, 11 October 2017
Line 29:		Line 29:
	*Half-life:		*Half-life:
	*Metabolism:		*Metabolism:
	*Excretion:		*Excretion: Urine 10-40%

	==Mechanism of Action==		==Mechanism of Action==

Humanguy: edited dosage form, strengths, routes of administration

2017-10-11T22:32:31Z

edited dosage form, strengths, routes of administration

← Older revision		Revision as of 22:32, 11 October 2017
Line 2:		Line 2:
	*Type: Topical antibiotic		*Type: Topical antibiotic
	*Dosage Forms: ointment		*Dosage Forms: ointment
	*Routes of Administration: topical, IM		*Dosage strengths: 500 unit/g
	*Common Trade Names:		*Routes of Administration: topical, ophthalmic, IM
			*Common Trade Names: BACiiM, Baciguent, Bacitracin Ophthalmic Ointment

	==Adult Dosing==		==Adult Dosing==

ClaireLewis at 15:49, 7 September 2016

2016-09-07T15:49:13Z

← Older revision		Revision as of 15:49, 7 September 2016
Line 1:		Line 1:
	==Administration==		==Administration==
	*Type:		*Type: Topical antibiotic
	*Dosage Forms:		*Dosage Forms: ointment
	*Routes of Administration:		*Routes of Administration: topical, IM
	*Common Trade Names:		*Common Trade Names:

	==Adult Dosing==		==Adult Dosing==
			*Apply to wound 2-5 times per day

	==Pediatric Dosing==		==Pediatric Dosing==
			*Apply to wound 2-5 times per day
			*Staph pneumonia/empyema known to be susceptible to bacitracin: 900-1000 units/kg/day IM in 2 to 3 divided doses
	==Special Populations==		==Special Populations==
	*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]:		*[[Drug Ratings in Pregnancy\|Pregnancy Rating]]: C
	*[[Lactation risk categories\|Lactation risk]]:		*[[Lactation risk categories\|Lactation risk]]: Infant risk minimal
	~~===~~Renal ~~Dosing===~~		*Renal: no adjustment
	*Adult:		*Hepatic: No adjustment
	*~~Pediatric:~~
	~~===~~Hepatic ~~Dosing===~~
	*Adult:
	*Pediatric:

	==Contraindications==		==Contraindications==
Line 24:		Line 22:
	==Adverse Reactions==		==Adverse Reactions==
	===Serious===		===Serious===
			*Renal toxicity (IM only)
	===Common===		===Common===
			*Contact dermatitis
	==Pharmacology==		==Pharmacology==
	*Half-life:		*Half-life:
Line 33:		Line 31:

	==Mechanism of Action==		==Mechanism of Action==
			*Interferes with cell wall peptidoglycan activity
			*Active against staph

	==Comments==		==Comments==

Cheejyg: Created page with "==Administration== Type: Dosage Forms: Routes of Administration: Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Drug Ratings in..."

2016-03-30T16:44:31Z

Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Drug Ratings in..."

New page

==Administration==
*Type:
*Dosage Forms:
*Routes of Administration:
*Common Trade Names:

==Adult Dosing==

==Pediatric Dosing==

==Special Populations==
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]:
*[[Lactation risk categories|Lactation risk]]:
===Renal Dosing===
*Adult:
*Pediatric:
===Hepatic Dosing===
*Adult:
*Pediatric:

==Contraindications==
*Allergy to class/drug

==Adverse Reactions==
===Serious===

===Common===

==Pharmacology==
*Half-life:
*Metabolism:
*Excretion:

==Mechanism of Action==

==Comments==

==See Also==

==References==
<references/>
[[Category:Pharmacology]]